01063cam0 2200277 450 E60020006655120241112113012.0887812005720100921d1987 |||||ita|0103 baitaIT<<Il >>futuro delle bibliotecheatti del 33. Congresso nazionale dell'Associazione italiana bibliotecheSirmione, 8-11 maggio 1986a cura di Giuseppe Origgie Gianni StefaniniRomaAssociazione italiana biblioteche1987360 p.ill.21 cmOriggi, GiuseppeA600200062298070Stefanini, GianniA600200062299070*ASSOCIAZIONE ITALIANA BIBLIOTECHEAF00024575070104838ITUNISOB20241112RICAUNISOBUNISOB01051553E600200066551M 102 Monografia moderna SBNM010000091Si51553acquistocatenacciUNISOBUNISOB20100921130415.020241112113012.0rovitoFuturo delle biblioteche154266UNISOB03159nam 22006495 450 991048313340332120251113185014.03-030-68180-710.1007/978-3-030-68180-7(CKB)4100000011807264(MiAaPQ)EBC6525798(Au-PeEL)EBL6525798(OCoLC)1243305466(PPN)254720080(DE-He213)978-3-030-68180-7(EXLCZ)99410000001180726420210323d2021 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierProteinkinase Inhibitors /edited by Stefan Laufer1st ed. 2021.Cham :Springer International Publishing :Imprint: Springer,2021.1 online resource (259 pages) illustrationsTopics in Medicinal Chemistry,1862-247X ;363-030-68179-3 Includes bibliographical references.ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.Topics in Medicinal Chemistry,1862-247X ;36Pharmaceutical chemistryProteinsBioorganic chemistryPharmaceutical chemistryMedicinal ChemistryProtein BiochemistryBioorganic ChemistryPharmaceuticsPharmaceutical chemistry.Proteins.Bioorganic chemistry.Pharmaceutical chemistry.Medicinal Chemistry.Protein Biochemistry.Bioorganic Chemistry.Pharmaceutics.572.792Laufer StefanMiAaPQMiAaPQMiAaPQBOOK9910483133403321Proteinkinase inhibitors1902275UNINA